SABCS 2021: Brain Metastases Updates in Breast Cancer
Focusing on datasets from the SABCS 2021 Virtual Meeting, panelists consider novel approaches to the management of brain metastases in breast cancer.
Data from the following clinical trials are discussed:
- PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis in HER2+ breast cancer: Results from TBCRC049, a phase 2 nonrandomized study
- PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB)
- P1-18-26: Intracranial efficacy of tucatinib, palbociclib, and letrozole combination in patients with HR+/HER2+ breast cancer and brain metastases
- P1-21-03: Efficacy of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2+ breast cancer with or without brain metastases: a systematic review and meta-analysis
- OT1-13-01: HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases
Related Videos
Related Content
